Merck & Co.’s stock was flat on Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Intel Corporation, one of the world's largest semiconductor designers and manufacturers, have begun the implementation of ...

M Chemical, a chemical subsidiary of Merck Korea, has been fully integrated into the German life science and electronics company's semiconductor entity. Starting from Monday, M Chemical is under ...

Are you a print subscriber? Activate your account. By Tim Nudd - 2 hours 18 min ago By Babar Rahman - 4 hours 13 min ago By Tim Nudd - 7 hours 53 min ago By Brian Bonilla - 9 hours 12 min ago 9 ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. After a pivotal trial failure two years ago in unresected locally advanced head and neck ...

AIDDISON is Merck’s AI-powered drug discovery platform that integrates AI-powered molecule design, synthesis planning and direct sourcing of chemical building blocks to accelerate the journey ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck in Germany was possibly the earliest company ... Pfizer was founded in 1849 by two German immigrants, initially as a fine chemicals business. Their business expanded rapidly during the ...

Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a perioperative regimen in certain patients with head and neck cancer ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.